SCHEMBL6077911

SCHEMBL6077911

CC#CCC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4827904 0.88
SCHEMBL14378315 0.87 ESR1 (0.32)
SCHEMBL237734 0.86 CYP1A2 (0.37)
SCHEMBL14979154 0.82 GBA1 (0.33)
SCHEMBL3259397 0.82
SCHEMBL9432413 0.82
SCHEMBL18477017 0.82 LIPA (0.30)
SCHEMBL14979153 0.80 NCF1 (0.48)
SCHEMBL23946062 0.77 SMN1; SMN2 (0.38)
SCHEMBL9820556 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7045529-B2 Imidazopyrimidinyl and imidazopyri dinyl derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-16 US claimed
US-20040229887-A1 Novel imidazopyrimidinyl and imidazopyri dinyl derivatives BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-11-18 US claimed
EP-1090005-B1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2003-08-20 EP claimed
US-6509338-B1 Psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, BRISTOL-MYERS SQUIBB COMPANY 2003-01-21 US claimed
EP-1244666-A1 IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES Bristol-Myers Squibb Pharma Company (US) 2002-10-02 EP claimed
WO-2001044248-A1 IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-06-21 WO claimed
EP-1090005-A1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS Du Pont Pharmaceuticals Company (US) 2001-04-11 EP claimed
WO-1999067247-A1 PYRAZOLO[1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-12-29 WO claimed
WO-2022100623-A1 NITROGEN-SUBSTITUTED HETEROCYCLIC THIOPHENE COMPOUNDS AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-05-19 WO disclosed
US-7045529-B2 Imidazopyrimidinyl and imidazopyri dinyl derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-16 US disclosed
US-20040229887-A1 Novel imidazopyrimidinyl and imidazopyri dinyl derivatives BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-11-18 US disclosed
EP-1090005-B1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2003-08-20 EP disclosed
US-6509338-B1 Psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, BRISTOL-MYERS SQUIBB COMPANY 2003-01-21 US disclosed
EP-1244666-A1 IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES Bristol-Myers Squibb Pharma Company (US) 2002-10-02 EP disclosed
WO-2001044248-A1 IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-06-21 WO disclosed
EP-1090005-A1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS Du Pont Pharmaceuticals Company (US) 2001-04-11 EP disclosed
WO-1999067247-A1 PYRAZOLO[1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-12-29 WO disclosed
CN-1188471-A 1,4-disubstituted piepridine derivatives BANYU PHARMA CO LTD (JP) 1998-07-22 CN disclosed
EP-0832084-A1 NOVEL DERIVATIVES OF SWAINSONINE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS Glycodesign Inc. (CA) 1998-04-01 EP disclosed
WO-1996040683-A1 NOVEL DERIVATIVES OF SWAINSONINE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS GLYCODESIGN INC. (CA) 1996-12-19 WO disclosed